KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

About this update from Koru Medical Systems, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/30379b281bf61e28b9c9b4785c5eb2e6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2Lkv.6AK77ku7z.tyA1nXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/30379b281bf61e28b9c9b4785c5eb2e6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/iu_DgeDlPDs3o63.8U90LQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/30379b281bf61e28b9c9b4785c5eb2e6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MAHWAH, N.J., January 12, 2026--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025.","length":429,"tagName":"p"},{"type":"text","content":"Financial Results (unaudited)","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9 million, representing growth of 23% over the prior year period","length":139,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Preliminary, unaudited full year 2025 net revenues expected to be $41.1 million, representing growth of 22% over the prior year","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ending cash balance of $8.9 million, representing positive cash flow in the fourth quarter and positive cash flow from operations for the full year","length":147,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":413,"olType":false},{"type":"text","content":""We delivered strong fourth quarter results and enter 2026 with solid momentum, driven by continued strength in our core immunoglobulin business and growth in our recurring patient base," said Linda Tharby, President and CEO of KORU Medical. "Our international expansion strategy is on track, and our re...

More updates from Koru Medical Systems, Inc.